EGFR and non-small cell lung carcinoma: Recently, the Dutch Healthcare Institute evaluated the budget impact of first-line osimertinib in NSCLC patients with EGFR mutations in the Netherlands over a 3-year horizon showing an estimated incremental budget impact of €18.6 million to €37.1 million [31].